SCHEMBL13629345

SCHEMBL13629345

CCc1ccc(NS(=O)(=O)c2cccc(OC)c2)cc1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 6/20 0.61
FFAR4 Q5NUL3 1/20 0.60
LMNA P02545 4/20 0.57
ALDH1A1 P00352 3/20 0.57
HTT P42858 2/20 0.57
ALOX15 P16050 1/20 0.57
MAPK1 P28482 1/20 0.57
PKM P14618 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
HPGD P15428 1/20 0.55
GAA P10253 1/20 0.55
RORA P35398 1/20 0.54
RORC P51449 1/20 0.54
NR1H2 P55055 1/20 0.54
AURKA O14965 1/20 0.54
KDR P35968 1/20 0.54
AURKB Q96GD4 1/20 0.54
HDAC3 O15379 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC1 Q13547 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13629409 0.86 PGR (0.60) PGRFFAR4LMNAALDH1A1HTT
SCHEMBL13629552 0.85 PKM (0.74) PGRFFAR4LMNAALDH1A1MAPK1
SCHEMBL13629416 0.84 ALDH1A1 (0.60) PGRLMNAALDH1A1HTTMAPK1
SCHEMBL13852925 0.82 PKM (0.75) PGRLMNAALDH1A1ALOX15PKM
SCHEMBL13615069 0.81 PGR (0.60) PGRFFAR4LMNAALDH1A1HTT
SCHEMBL13629464 0.79 ALDH1A1 (0.77) LMNAALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL13629330 0.79 HSD17B2 (0.68) PGRFFAR4MAPK1PKMGAA
SCHEMBL3758000 0.78 PGR (0.83) PGRFFAR4LMNAALDH1A1GAA
SCHEMBL6701809 0.77 AURKA (0.70) PGRFFAR4LMNAALDH1A1HTT
SCHEMBL7181531 0.77 PGR (0.72) PGRFFAR4LMNAALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK PGR 1506/4885FFAR4 3554/4885LMNA 2891/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK PGR 1648/4885FFAR4 3913/4885LMNA 2608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.